Skip to content
The Nexus
DossierENTITY

Forte Biosciences

Coverage of Forte Biosciences in the Nexus archive.

Earliest in view: Jul 27 · 07:26 UTCMost recent: Jul 27 · 07:26 UTC
Co-mentioned in this coverage
Argenxorganization1Vyvgarttopic1Dallasplace1Belgiumplace1
Recent coverage
  • BUSINESSJul 27 · 07:26 UTCSTAT NEWS
    STAT+: Argenx to buy Forte Biosciences for $2.2B

    Argenx agreed to acquire Forte Biosciences for $2.2 billion in cash, valuing the Dallas-based company at $77 per share, a 41% premium. The deal aims to expand Argenx's immunology pipeline, leveraging its success with the autoimmune drug Vyvgart.

Forte Biosciences · Dossier · The Nexus